Study design
Observational, retrospective, multicentre study in a realworld setting utilising follow-up data from 10 Spanish and 2 Portuguese outpatient centres.

Aim
To evaluate the effectiveness of PLENVU^® in overall bowel cleansing success and high-quality cleansing in the right colon, in a large sample of patients in a real-world setting.

Patients
A total of 13,169 patients aged ≥18 years who underwent a screening, surveillance or diagnostic colonoscopy between June 2019 and September 2021 as an outpatient.

Treatments
Overnight split-dose (evening and morning) or same day morning dosing regimen with PLENVU^®.

Endpoints
Overall adequate-quality colon cleansing:

• Total BBPS score ≥6, with all segmental scores ≥2.
  High-quality cleansing of the right colon:
• BBPS=3.

Overall high-quality colon cleansing:

• Total BBPS score ≥8

Exploratory endpoints:

• Polyp and adenoma detection rates in the total and right colon
• Caecal intubation time
• Colonoscopy withdrawal time.
  Safety determined from recorded adverse events.
  The efficacy and safety of PLENVU^® in patients aged ≥65 years versus <65 years was also assessed.

Statistical analysis
For categorical variables, the frequency and percentage were calculated and for proportion values, 95% confidence intervals were calculated using the Wilcoxon method. The Chi-square test was used to compare outcomes in the subgroups of patients treated using overnight split versus same-day dosing, and aged ≥65 versus <65 years; Fisher’s exact test was applied if the proportion of expected values less than 5 was higher than 20%.

Reference: 1. López-Jamar JME, et al. Endosc Int Open. 2023;11(8):E785-E793.